Search details
1.
Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics.
Eur J Nucl Med Mol Imaging
; 2024 May 09.
Article
in English
| MEDLINE | ID: mdl-38724653
2.
Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.
Int J Mol Sci
; 24(23)2023 Nov 28.
Article
in English
| MEDLINE | ID: mdl-38069166
3.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol
; 22(8): 1115-1125, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34246328
4.
A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89Zr PET Imaging.
Molecules
; 26(19)2021 Sep 25.
Article
in English
| MEDLINE | ID: mdl-34641362
5.
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study.
Eur J Nucl Med Mol Imaging
; 45(8): 1364-1371, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29644393
6.
Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives.
Int J Mol Sci
; 19(2)2018 Feb 02.
Article
in English
| MEDLINE | ID: mdl-29393868
7.
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
J Urol
; 196(2): 382-91, 2016 08.
Article
in English
| MEDLINE | ID: mdl-26964917
8.
In vivo biokinetic and metabolic characterization of the 68Ga-labelled α5ß1-selective peptidomimetic FR366.
Eur J Nucl Med Mol Imaging
; 43(5): 953-963, 2016 May.
Article
in English
| MEDLINE | ID: mdl-26497698
9.
Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging
; 46(10): 2212-2213, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31273434
10.
Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape.
J Exp Clin Cancer Res
; 43(1): 41, 2024 Feb 06.
Article
in English
| MEDLINE | ID: mdl-38317202
11.
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.
EJNMMI Radiopharm Chem
; 9(1): 18, 2024 Feb 26.
Article
in English
| MEDLINE | ID: mdl-38407630
12.
Selective imaging of the angiogenic relevant integrins α5ß1 and αvß3.
Angew Chem Int Ed Engl
; 52(44): 11656-9, 2013 Oct 25.
Article
in English
| MEDLINE | ID: mdl-24115324
13.
Prognostic Role of 68Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
J Nucl Med
; 64(6): 896-901, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36581373
14.
The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
J Nucl Med
; 64(8): 1252-1258, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37290796
15.
177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers.
J Nucl Med
; 64(3): 402-409, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36137758
16.
Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
J Nucl Med
; 64(8): 1244-1251, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37321824
17.
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T.
J Nucl Med
; 64(11): 1765-1771, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37678925
18.
Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.
EJNMMI Res
; 12(1): 5, 2022 Jan 31.
Article
in English
| MEDLINE | ID: mdl-35099641
19.
Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer.
J Nucl Med
; 63(10): 1489-1495, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35086894
20.
Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med
; 63(6): 833-839, 2022 06.
Article
in English
| MEDLINE | ID: mdl-34531260